Degradation of topoisomerase I induced by topoisomerase I inhibitors is dependent on inhibitor structure but independent of cell death

Molecular Pharmacology

Volumn 55, Issue 4, 1999, Pages 677-683

  Fu, Qin ^a   Kim, Seung Whan ^a   Chen, Hong Xin ^a   Grill, Susan ^a   Cheng, Yung Chi ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 FORMYLAMINO 12,13 DIHYDRO 1,11 DIHYDROXY 5H INDOLO[2,3 A][PYRROLO[3,4 C]CARBAZOLE 5,7(6H) DIONE 13 GLUCOSIDE; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; EPIPODOPHYLLOTOXIN DERIVATIVE; PROTEASOME; TOPOTECAN; UNCLASSIFIED DRUG; W 1; W 2;

ARTICLE; CELL DEATH; COMPLEX FORMATION; DRUG EFFECT; DRUG STRUCTURE; ENZYME DEGRADATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 0032891175     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Bastow KF, Wang HK, Cheng YC and Lee KH (1997) Antitumor agents - CLXXIII. Synthesis and evaluation of camptothecin-4 beta-amino-4′-O-demethyl epipodophyllotoxin conjugates as inhibitors of mammalian DNA topoisomerases and as cytotoxic agents. Bioorg Med Chem 5:1481-1488.
2. Beidler DR, Chang JY, Zhou BS and Cheng YC (1996) Camptothecin resistance involving steps subsequent to the formation of protein-linked DNA breaks in human camptothecin-resistant KB cell lines. Cancer Res 56:345-353.
3. Beidler DR and Cheng YC (1995) Camptothecin induction of a time-and concentration-dependent decrease of topoisomerase I and its implication in camptothecin activity. Mol Pharmacol 47:907-914.
4. Buckwalter CA, Lin AH, Tanizawa A, Pommier Y, Cheng YC and Kaufmann SH (1996) RNA synthesis inhibitors alter the subnuclear distribution of DNA topoisomerase I. Cancer Res 56:1674-1681.
5. Danks MK, Garrett KE, Marion RC and Whipple DO (1996) Subcellular redistribution of DNA topoisomerase I in anaplastic astrocytoma cells treated with topotecan. Cancer Res 56:1664-1673.
6. Desai SD, Liu LF, Vazquez-Abad D and D'Arpa P (1997) Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin. J Biol Chem 272:24159-24164.
7. Downes CS and Johnson RT (1988) DNA topoisomerases and DNA repair. Bioessays 8:179-184.
8. Fenteany G and Schreiber SL (1998) Lactacystin, proteasome function, and cell fate. J Biol Chem 273:8545-8548.
9. Fenteany G, Standaert RF, Lane WS, Choi S, Corey EJ and Schreiber SL (1995) Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science (Wash DC) 268:726-731.
10. Fukasawa K, Komatani H, Hara Y, Suda H, Okura A, Nishimura S and Yoshinari T (1998) Sequence-selective DNA cleavage by a topoisomerase I poison, NB-506. Int J Cancer 75:145-150.
11. Ghoda L, Lin X and Greene WC (1997) The 90-kDa ribosomal S6 kinase (pp90rsk) phosphorylates the N-terminal regulatory domain of IκBα and stimulates its degradation in vitro. J Biol Chem 272:21281-21288.
12. Glas R, Bogyo M, McMaster JS, Gaczynska M and Ploegh HL (1998) A proteolytic system that compensates for loss of proteasome function. Nature (London)392: 618-622.
13. Hsiang YH, Hertzberg R, Hecht S and Liu LF (1985) Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260: 14873-14878.
14. Hsiang YH, Lihou MG and Liu LF (1989) Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49:5077-5082.
15. Kaufmann, SH (1998) Cell death induced by topoisomerase-targeted drugs: More questions than answers. Biochim Biophys Acta 1400:195-211
16. Krek W (1998) Proteolysis and the G1-S transition: The SCF connection. Curr Opin Genet Dev 8:36-42.
17. Liu LF, Duann P, Lin CT, D'Arpa P and Wu J (1996) Mechanism of action of camptothecin. Ann NY Acad Sci 803:44-49.
18. Nannmark U, Kitson RP, Johansson BR, Rivett AJ and Goldfarb RH (1996) Immunocytochemical localization of multicatalytic protease complex (proteasome) during generation of murine IL-2-activated natural killer (A-NK) cells. Eur J Cell Biol 71:402-408.
19. Palmer A, Mason GG, Paramio JM, Knecht E and Rivett AJ (1994) Changes in proteasome localization during the cell cycle. Eur J Cell Biol 64:163-175.
20. Pommier, Y, Gupta M, Valenti M and Nieves-Neira W (1996) Cellular resistance to camptothecins. Ann NY Acad Sci 803:60-73.
21. Pommier Y, Leteurtre F, Fesen MR, Fujimori A, Bertrand R, Solary E, Kohlhagen G and Kohn KW (1994) Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Investig 12:530-542.
22. Porter SE and Champoux JJ (1989) The basis for camptothecin enhancement of DNA breakage by eukaryotic topoisomerase I. Nucleic Acids Res 17:8521-8532.
23. Redinbo MR, Stewart L, Kuhn P, Champoux JJ and Hol WG (1998) Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. Science (Wash DC) 279:1504-13.
24. Rivett AJ, Palmer A and Knecht E (1992) Electron microscopic localization of the multicatalytic proteinase complex in rat liver and in cultured cells. J Histochem Cytochem 40:1165-1172.
25. Roca J (1995) The mechanisms of DNA topoisomerases. Trends Biochem Sci 20:156-160.
26. Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, Hwang D and Goldberg AL (1994) Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 78:761-771.
27. Rothenberg ML (1997) Topoisomerase I inhibitors: Review and update. Ann Oncol 8:837-855.
28. Sreedharan SK, Verma C, Caves LS, Brocklehurst SM, Gharbia SE, Shah HN and Brocklehurst K (1996) Demonstration that 1-trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane (E-64) is one of the most effective low Mr inhibitors of trypsin-catalysed hydrolysis. Characterization by kinetic analysis and by energy minimization and molecular dynamics simulation of the E-64-beta-trypsin complex. Biochem J 316:777-786.
29. Stewart L, Redinbo MR, Qiu X, Hol WG and Champoux JJ (1998) A model for the mechanism of human topoisomerase I. Science (Wash DC) 279:1534-1541.
30. Wall ME and Wani MC (1996) Camptothecin. Discovery to clinic. Ann NY Acad Sci 803:1-12.
31. Wang JC (1996) DNA topoisomerases. Annu Rev Biochem 65:635-692.
32. Wang LF, Ting CY, Lo CK, Su JS, Mickley LA, Fojo AT, Whang-Peng J and Hwang J (1997) Identification of mutations at DNA topoisomerase I responsible for camptothecin resistance. Cancer Res 57:1516-1522.
33. Whitesell L, Sutphin P, An WG, Schulte T, Blagosklonny MV and Neckers L (1997) Geldanamycin-stimulated destabilization of mutated p53 is mediated by the proteasome in vivo. Oncogene 14:2809-2816.
34. Yoshinari T, Matsumoto M, Arakawa H, Okada H, Noguchi K, Suda H, Okura A and Nishimura S (1995) Novel antitumor indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13-(beta-D-glucopyranosyl)-5H- indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506): Induction of topoisomerase I-mediated DNA cleavage and mechanisms of cell line-selective cytotoxicity. Cancer Res 55:1310-1315.
35. Zhou BS, Bastow KF and Cheng YC (1989) Characterization of the 3′ region of the human DNA topoisomerase I gene. Cancer Res 49:3922-7.